RxDoctor Payments Data

Marilyn Barnhill

Psychiatric/Mental Health · Lubbock, TXNPI 1598953572

Payments from drug & device makers

$3,733in general payments, 2019–2025

Across 68 payments — averaging $54.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$593
  • Johnson & Johnson$351
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$191
  • Teva Pharmaceuticals USA, Inc.$111
  • Otsuka America Pharmaceutical, Inc.$66
  • plus $140 from 3 others

What the payments were for

  • Speaking & faculty fees$2,00054%
  • Food & beverage$1,58642%
  • Education$1474%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,733 in reported general payments places this provider in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$8,758
Medicare patients
49
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate116$326,131
IngrezzaValbenazine Tosylate29$238,300
VraylarCariprazine Hcl105$151,933
Abilify MaintenaAripiprazole31$85,171
RexultiBrexpiprazole37$51,480
CaplytaLumateperone Tosylate12$21,049
LatudaLurasidone Hcl12$15,782
Lurasidone Hcl75$11,469
Paliperidone ErPaliperidone48$9,396
Olanzapine202$5,157
Quetiapine Fumarate335$5,131
Ziprasidone Hcl130$5,030
Clozapine47$4,384
Aripiprazole92$3,970
Haloperidol170$3,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$351$326,131116 claims
Neurocrine Biosciences, Inc.Ingrezza$593$238,30029 claims
AbbVieVraylar$2,282$151,933105 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$66$136,65168 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$191$21,04912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →